REFERENCES
1. Kaliberov SA, Buchsbaum DJ. Cancer treatment with gene therapy and radiation therapy. Adv Cancer Res 2012;115:221-63.
2. Kushwaha PP, Rapalli KC, Kumar S. Geminin a multi task protein involved in cancer pathophysiology and developmental process: a review. Biochimie 2016;131:115-27.
3. Kumar S, Kushwaha PP, Gupta S. Emerging targets in cancer drug resistance. Cancer Drug Resist 2019;2:161-77.
4. Falasca M, Linton KJ. Investigational ABC transporter inhibitors. Expert OpinInvestig Drugs 2012;21:657-66.
5. Kushwaha PP, Singh AK, Shuaib M, et al. 3-O-(E)-p-Coumaroylbetulinic acid possess anticancer activity and inhibit notch signaling pathway in breast cancer cells and mammosphere. ChemBiol Interact 2020;328:1-9.
6. Kinghorn AD, Chin YW, Swanson SM. Discovery of natural product anticancer agents from biodiverse organisms. Curr Opinion Drug Dis Dev 2009;12:189-96.
7. Pinar R. To investigate knowledge of Turkish people about cancer. Cancer Agenda 1998;12:66-73.
8. Tambama P, Abegaz B, Mukanganyama S. Antiproliferative activity of the isofuranonaphthoquinone isolated from Bulbinefrutescens against jurkat T cells. BioMed Res Int 2014;2014:1-14.
9. van Huyssteen M, Milne PJ, Campbell EE, van de Venter M. Antidiabetic and cytotoxicity screening of five medicinal plants used by traditional African health practitioners in the Nelson Mandela Metropole, South Africa. Afr J Tradit Complement Altern Med 2011;8:150-8.
10. Mukanganyama S, Bezabih M, Robert M, et al. The evaluation of novel natural products as inhibitors of human glutathione transferase P1-1. J Enzyme Inhib Med Chem 2011;26:460-7.
11. Kushwaha PP, Vardhan PS, Kapewangolo P, et al.
12. Ezebuo FC, Kushwaha PP, Singh AK, Kumar S, Singh P. In silico methods of drug design: molecular simulations and free energy calculations. In: Kumar S, Chukwuebuka E, editors. Phytochemistry: An in-silico and in-vitro Update. Singapore: Springer; 2019. pp. 521-33.
13. Kushwaha PP, Kumar A, Maurya S, Singh AK, Sharma AK, Kumar S. Bulbine frutescens phytochemicals as a promising anti-cancer drug discovery source: a computational study. In: Phytochemistry: An in-silico and in-vitro Update. Singapore: Springer; 2019. pp. 491-510.
14. O’Boyle NM, Banck M, James CA, et al. Open babel: an open chemical toolbox. J Cheminformatics 2011;3:1-14.
15. Dallakyan S. PyRx-python prescription v. 0.8. The Scripps Research Institute 2010. Available from: https://pyrx.sourceforge.io/. [Last accessed on 31 Dec 2020].
16. Berman H, Henrick K, Nakamura H, Markley JL. The worldwide Protein Data Bank (wwPDB): ensuring a single, uniform archive of PDB data. Nucleic Acids Res 2007;35:301-3.
17. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera - a visualization system for exploratory research and analysis. J ComputChem 2004;25:1605-12.
18. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31:455-461.
19. Gupta S, Singh AK, Kushwaha PP, et al. Identification of potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studies. J Biomol Struct Dyn 2020:1-9.
20. Fox E, Bates SE. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 2007;7:447-59.
21. Jouan E, Le Vée M, Mayati A, et al. Evaluation of P-glycoprotein inhibitory potential using a rhodamine 123 accumulation assay. Pharmaceutics 2016;82:1-13.
23. Aller SG, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009;323:1718-22.
24. Di Meo F, Fabre G, Berka K, et al. In silico pharmacology: drug membrane partitioning and crossing. Pharmacol Res 2016;111:471-86.
